CMS cuts deal on four oncology drugs under Medicare

Medicare Part B premiums expected to rise almost 10% in 2026

Centers for Medicare and Medicaid Services has announced that monthly premiums for Medicare Part B will begin costing patients $202.09 per month next year—a 9.7% rise up from $185 in 2025—for individuals making an annual income of $109,000 or less.

December 05, 2025

By Sara Willa Ernst

Cancer Policy

Hospitals sue to block CMS 340B drug rebate pilot

The American Hospital Association, joined by four community-based hospitals, has sued HHS over a pilot program to reimburse drug costs to safety net hospitals enrolled in the 340B program through a rebate—a departure of the status quo of up-front discounts.

December 05, 2025

By Sara Willa Ernst

Cancer Policy

CMS announces GENEROUS drug payment model aimed at lowering Medicaid drug prices

CMS announced a new drug payment model called the GENErating cost Reductions for U.S. Medicaid (GENEROUS) Model that the agency plans to pilot next year.

November 14, 2025

Vol.51 No.42

By Sara Willa Ernst and Jacquelyn Cobb

Cancer Policy

White House makes deal with Eli Lilly, Novo Nordisk to lower weight loss drug prices and begin Medicare coverage

The White House Nov. 6 announced a deal with drugmakers Eli Lilly and Co. and Novo Nordisk to expand coverage and reduce prices for their obesity treatments, Zepbound and Wegovy.

Dems push GOP to extend ACA credits as part of a deal to end the government shutdown

Millions of Americans with Affordable Care Act marketplace health insurance will face higher costs next year if Congress doesn’t extend enhanced premium tax credits that have made the plans more affordable for low- and middle-income enrollees.

October 17, 2025

Vol.51 No.38

By Claire Marie Porter